Literature DB >> 11513604

Cleavage of 3',5'-pyrophosphate-linked dinucleotides by ribonuclease A and angiogenin.

A M Jardine1, D D Leonidas, J L Jenkins, C Park, R T Raines, K R Acharya, R Shapiro.   

Abstract

Recently, 3',5'-pyrophosphate-linked 2'-deoxyribodinucleotides were shown to be >100-fold more effective inhibitors of RNase A superfamily enzymes than were the corresponding monophosphate-linked (i.e., standard) dinucleotides. Here, we have investigated two ribo analogues of these compounds, cytidine 3'-pyrophosphate (P'-->5') adenosine (CppA) and uridine 3'-pyrophosphate (P'-->5') adenosine (UppA), as potential substrates for RNase A and angiogenin. CppA and UppA are cleaved efficiently by RNase A, yielding as products 5'-AMP and cytidine or uridine cyclic 2',3'-phosphate. The k(cat)/K(m) values are only 4-fold smaller than for the standard dinucleotides CpA and UpA, and the K(m) values (10-16 microM) are lower than those reported for any earlier small substrates (e.g., 500-700 microM for CpA and UpA). The k(cat)/K(m) value for CppA with angiogenin is also only severalfold smaller than for CpA, but the effect of lengthening the internucleotide linkage on K(m) is more modest. Ribonucleotide 3',5'-pyrophosphate linkages were proposed previously to exist in nature as chemically labile intermediates in the pathway for the generation of cyclic 2',3'-phosphate termini in various RNAs. We demonstrate that in fact they are relatively stable (t(1/2) > 15 days for uncatalyzed degradation of UppA at pH 6 and 25 degrees C) and that cleavage in vivo is most likely enzymatic. Replacements of the RNase A catalytic residues His12 and His119 by alanine reduce activity toward UppA by approximately 10(5)-and 10(3.3)-fold, respectively. Thus, both residues play important roles. His12 probably acts as a base catalyst in cleavage of UppA (as with RNA). However, the major function of His119 in RNA cleavage, protonation of the 5'-O leaving group, is not required for UppA cleavage because the pK(a) of the leaving group is much lower than that for RNA substrates. A crystal structure of the complex of RNase A with 2'-deoxyuridine 3'-pyrophosphate (P'-->5') adenosine (dUppA), determined at 1.7 A resolution, together with models of the UppA complex based on this structure suggest that His119 contributes to UppA cleavage through a hydrogen bond with a nonbridging oxygen atom in the pyrophosphate and through pi-pi stacking with the six-membered ring of adenine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513604     DOI: 10.1021/bi010888j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

2.  Recognition of ribonuclease A by 3'-5'-pyrophosphate-linked dinucleotide inhibitors: a molecular dynamics/continuum electrostatics analysis.

Authors:  Savvas Polydoridis; Demetres D Leonidas; Nikos G Oikonomakos; Georgios Archontis
Journal:  Biophys J       Date:  2006-12-01       Impact factor: 4.033

3.  A new crystal form of bovine pancreatic RNase A in complex with 2'-deoxyguanosine-5'-monophosphate.

Authors:  Steven B Larson; John S Day; Robert Cudney; Alexander McPherson
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-31

4.  Inhibitor design for ribonuclease A: the binding of two 5'-phosphate uridine analogues.

Authors:  Vicky G Tsirkone; Kyriaki Dossi; Christina Drakou; Spyros E Zographos; Maria Kontou; Demetres D Leonidas
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

5.  High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.

Authors:  Demetres D Leonidas; Gayatri B Chavali; Nikos G Oikonomakos; Evangelia D Chrysina; Magda N Kosmopoulou; Metaxia Vlassi; Claire Frankling; K Ravi Acharya
Journal:  Protein Sci       Date:  2003-11       Impact factor: 6.725

6.  A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.

Authors:  Richard Y T Kao; Jeremy L Jenkins; Karen A Olson; Marc E Key; James W Fett; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-12       Impact factor: 11.205

7.  Nucleotide substrate binding characterization in human pancreatic-type ribonucleases.

Authors:  Khushboo Bafna; Chitra Narayanan; S Chakra Chennubhotla; Nicolas Doucet; Pratul K Agarwal
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

8.  Bridging solvent molecules mediate RNase A - Ligand binding.

Authors:  Stefan M Ivanov; Ivan Dimitrov; Irini A Doytchinova
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

9.  Influence of naturally-occurring 5'-pyrophosphate-linked substituents on the binding of adenylic inhibitors to ribonuclease a: an X-ray crystallographic study.

Authors:  Daniel E Holloway; Gayatri B Chavali; Demetres D Leonidas; Matthew D Baker; K Ravi Acharya
Journal:  Biopolymers       Date:  2009-12       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.